Related Experiment Video
Updated: Jan 16, 2026
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Predicting treatment success in pediatric mild-to-moderate OSA: real-world evidence from a model based on
1Department of Otolaryngology Head and Neck Surgery, Affiliated Dongguan Maternal & Child Healthcare Hospital, No 99. Zhenxing Road, Dongguan, 523120, Guangdong Province, China. yuanm-wang@ldy.edu.rs.
Insights
A new model predicts how well children with obstructive sleep apnea (OSA) respond to intranasal corticosteroids (INCS). This tool helps personalize treatment for pediatric OSA by identifying early predictors of success.
Area of Science:
- Pediatric Pulmonology
- Sleep Medicine
- Clinical Prediction Modeling
Background:
- Pediatric mild-to-moderate obstructive sleep apnea (OSA) treatment with intranasal corticosteroids (INCS) shows variable response rates.
- Predicting treatment success early can enable personalized therapeutic approaches for children with OSA.
Purpose of the Study:
- To develop and validate a predictive model for INCS treatment response in pediatric mild-to-moderate OSA.
- To identify early clinical and polysomnographic predictors of treatment success.
Main Methods:
- A two-phase observational study involving a derivation cohort (n=175) and a prospective validation cohort (n=60) of children aged 3-12 years with OSA (AHI 1.0-10.0).
- Standardized INCS therapy was administered, with response defined as ≥50% AHI reduction and symptom improvement at 6-9 months.
- Multivariable logistic regression identified independent predictors, leading to a nomogram model validated in the prospective cohort.
Main Results:
- The developed nomogram model demonstrated good calibration and discrimination in predicting INCS response.
- Key clinical and polysomnographic parameters were identified as independent predictors of treatment success.
- External validation in a prospective cohort confirmed the model's predictive performance.
Conclusions:
- A validated nomogram model using polysomnography and clinical data can predict INCS treatment response in pediatric OSA.
- This model supports early clinical decision-making for personalized treatment strategies in children with OSA.
- The findings facilitate individualized therapy selection for pediatric obstructive sleep apnea.
Background:
Pediatric mild-to-moderate obstructive sleep apnea (OSA) is often treated with intranasal corticosteroids (INCS), but response rates vary. Identifying early predictors of treatment success may facilitate individualized therapy.
Methods:
We conducted a single-center, two-phase observational study to develop and validate a predictive model for INCS response in children aged 3-12 years with mild-to-moderate OSA, defined by a baseline apnea-hypopnea index (AHI) of 1.0-10.0 events/hour. The derivation cohort (n = 175) was retrospectively enrolled between 2019 and 2023. A prospective validation cohort (n = 60) was recruited between 2024 and 2025 using identical diagnostic and treatment protocols. All patients received standardized INCS therapy. Treatment response was defined as a ≥ 50% reduction in AHI along with improvement in clinical symptoms at 6-9 months follow-up.
Results:
Candidate predictors were extracted from baseline clinical and polysomnographic (PSG) parameters. Multivariable logistic regression was used to identify independent predictors. A predictive nomogram model was constructed based on these variables and externally validated in the prospective cohort. The model demonstrated good calibration and discrimination.
Conclusion:
This study presents a validated nomogram model based on PSG and clinical parameters to predict treatment response to INCS in pediatric OSA, supporting early decision-making and personalized treatment strategies.
